Press Releases September 3, 2026 04:35 PM

Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08

Teladoc Health grants inducement awards to new CFO under NYSE rules

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
TDOC

Teladoc Health announced inducement awards for Michael Grasher upon joining as Chief Financial Officer on September 1, 2026. The awards include restricted stock units and performance stock units tied to adjusted EBITDA and revenue growth targets. Vesting schedules extend through 2029 based on continued service and performance milestones.

Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08
TDOC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Teladoc Health appoints Michael Grasher as CFO and grants inducement awards including restricted and performance stock units.
  • Performance stock units are contingent on 2026 adjusted EBITDA and revenue growth targets through 2028.
  • Awards are structured with vesting over several years to incentivize long-term performance and retention.

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued inducement awards to a new employee.

Effective September 1, 2026, in connection with commencing employment as Chief Financial Officer, Michael Grasher was granted an award of restricted stock units covering 239,616 shares of Teladoc Health’s common stock, par value $0.001 per share (“Common Stock”), and awards of performance stock units covering a target of 239,616 shares of Common Stock (for which up to 479,232 shares may be earned). The restricted stock units vest, based on continued service to Teladoc Health as to one-half of the underlying shares on the first anniversary of the grant date, with the remainder vesting in six substantially equal quarterly installments beginning on the 15-month anniversary of the grant date. The performance stock units provide a target number of shares of Common Stock that would be earned based on (i) Teladoc Health’s adjusted EBITDA for 2026 (“EBITDA PSUs”) and (ii) Teladoc Health’s actual compound annual revenue growth rate during 2026-2028 (“Revenue CAGR PSUs”). One-half of any earned EBITDA PSUs would vest on the first anniversary of the grant date and the remaining one-half would vest in six substantially equal quarterly installments beginning on the 15-month anniversary of the grant date. Any earned Revenue CAGR PSUs would vest on March 1, 2029.

The awards were approved by the Compensation Committee of the Board of Directors of Teladoc Health and were granted under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan as employment inducement awards pursuant to New York Stock Exchange Rule 303A.08.

About Teladoc Health

Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at www.teladochealth.com.

Media:
Lou Serio
202-569-9715
[email protected]


Risks

  • Achievement of performance-based stock units depends on Teladoc Health meeting financial targets, posing execution risk for incentive realization.
  • Long vesting schedule means potential uncertainties in company performance or market conditions could impact the effective value of awards.
  • Changes in virtual healthcare industry dynamics or regulatory environment may affect company earnings and growth projections.

More from Press Releases

Tenable Uses OpenAI GPT Cyber Models to Help Defenders Inspect Community-Built AI Components Sep 3, 2026 XTEND Reality Expansion Ltd. and JFB Construction Holdings Complete Business Combination, Raising $110 Million in Total Capital Sep 3, 2026 Freshworks Announces Inducement Grant under Listing Rule 5635(C)(4) of the Nasdaq Stock Market Sep 3, 2026 Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS Sep 3, 2026 Rogers and Quebecor Agree to New 12-Year Sublicensing Deal for National NHL Games in French Sep 3, 2026